Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 3,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Recruiting Phase 1 Interventional

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT07219147
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Terminated Not applicable Interventional

PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

NCT02042053
View directory record Official record
Conditions
Prostate Cancer
Interventions
PET/CT, PET/MRI
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1

NCT01241656
View directory record Official record
Conditions
Healthy Men Age 50 Who Are Considering PSA Screening
Interventions
DESI for home viewing, DESI for viewing at Shared Medical Appointment, Option of SMA and DESI or DESI only
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
2,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Phase 2 Interventional

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

NCT04402151
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional Results available

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

NCT03300505
View directory record Official record
Conditions
Prostate Cancer
Interventions
ARRx, Enzalutamide
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy

NCT00054522
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00072722
View directory record Official record
Conditions
Prostate Cancer
Interventions
CC-4047
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Denver, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2006 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Not applicable Interventional

Exercise in Prostate Cancer

NCT06165302
View directory record Official record
Conditions
Prostate Cancer Metastatic, Prostate Cancer
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Not yet recruiting Not applicable Interventional

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer

NCT07769372
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration
Procedure · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method

NCT02025413
View directory record Official record
Conditions
Metastatic Progressive Castration-resistant Prostate Cancer, Metastatic Progressive Breast Cancer
Interventions
Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III Study

NCT05895279
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Media Intervention, Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 4 Interventional

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

NCT00029224
View directory record Official record
Conditions
Breast Cancer, Multiple Myeloma, Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
7
States / cities
Stockton, California • Kissimmee, Florida • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer

NCT02716974
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Bicalutamide, Docetaxel, Prostatectomy, Radiation
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer

NCT01792024
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage II Prostate Carcinoma
Interventions
Visualase Thermal Therapy, magnetic resonance imaging
Device · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
45 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 31, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

NCT01647789
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CFG920
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
San Francisco, California • San Antonio, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Phase 2 Interventional

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

NCT06865768
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

NCT01194960
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
Docetaxel, TroVax
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
San Bernardino, California • Stanford, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 1Phase 2 Interventional

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT04742959
View directory record Official record
Conditions
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
Interventions
TT-00420, Nab-Paclitaxel
Drug · Combination Product
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

NCT00078910
View directory record Official record
Conditions
Prostate Cancer
Interventions
exisulind, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging

NCT04981223
View directory record Official record
Conditions
Prostate Cancer
Interventions
ExactVu
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy

NCT00578123
View directory record Official record
Conditions
Prostate Cancer, Quality of Life
Interventions
Quality of Life Questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 31, 2026, 6:57 PM EDT
Active, not recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

NCT03976843
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Early Phase 1 Interventional

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 31, 2026, 6:57 PM EDT